| Abbott MitraClip system shows efficacy in new trial | Posted on 16/03/2010 in Medical Company Product News Abbott has published positive clinical trial data of a new catheter-based system for sufferers of mitral regurgitation (MR).
Results from the Everest II trial showed that the company's MitraClip system was able to provide significant benefits to those affected by MR, which causes blood leakage within the heart due to certain valves failing to completely close.
The MitraClip system uses a catheter-based device to repair this defect, allowing for improved heart function, reduced symptoms and a better quality of life.
Dr Charles Simonton, divisional vice-president of medical affairs and chief medical officer at Abbott Vascular, said these results will help physicians to more easily evaluate the benefits and risks of the treatment.
He said: "The MitraClip procedure has the potential to be an important addition to the current options for treating certain patients with significant MR."
This week has also seen the company provide encouraging data from a trial of its bioresorbable vascular scaffold technology, which can help to reduce the likelihood of blood clots.Other news stories from 16/03/2010
Read more in the Zenopa News Archive
How this news is generated
|  |
|
